Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy

Trial Profile

Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs Eplerenone (Primary) ; Spironolactone
  • Indications Duchenne muscular dystrophy
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 10 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top